U.S. market Closed. Opens in 11 hours 26 minutes

XRTX | XORTX Therapeutics Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for XRTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is very weak.

Valuation (10%)

Company Industry
P/E Ratio (TTM) -3.68 -16.22
PEG Ratio (TTM) -0.05 -1.41
P/S Ratio (TTM) N/A 48.82
P/B Ratio (TTM) 2.00 21.13
P/FCF Ratio (TTM) -1.21 9.38
Price to 5YR AVG Earnings Ratio -0.92 -0.21
Price to 5YR AVG FCF Ratio -1.27 -7.10

Profitability (25%)

Company Industry
ROA (TTM) -30.62% -3.10%
ROE (TTM) -36.98% 24.21%
Net Profit Margin (TTM) N/A -1,069.78%
ROIC 5YR AVG 790.55% 16.50%

Growth (33%)

4QTR AVG 3YR AVG 5YR AVG
EPS 60.50% 17.20% -35.94%
Revenue N/A N/A N/A
Net Income 54.49% -7.20% -80.36%
Cash Flow 14.80% -220.23% -144.16%

Health (32%)

Company Industry
Current Ratio (TTM) 1.58 5.75
Quick Ratio (TTM) 1.58 5.47
D/E Ratio (TTM) 0.03 -15.13
Interest Coverage (TTM) N/A 3.59
Piotroski F-Score 2 5
Altman Z-Score N/A 13.47
LTL to 5YR AVG FCF N/A 0.20
Shares Outstanding Growth 5YR AVG 28.61% 118.86%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙